File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: From complexity to simplicity: best level of evidence for metastatic colorectal cancer.

TitleFrom complexity to simplicity: best level of evidence for metastatic colorectal cancer.
Authors
KeywordsChemotherapy, adjuvant
Colorectal neoplasms
Receptor, epidermal growth factor
Vascular epidermal growth factor
Issue Date2013
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkjr.org
Citation
Hong Kong Journal of Radiology, 2013, v. 16 n. Suppl. , p. 9-16 How to Cite?
AbstractSimplicity is enormously complex in the treatment of metastatic colorectal cancer. In terms of survival, life expectancy of patients with metastatic colorectal cancer improved substantially from 3 to 6 months in the 1980s when only 5-fluorouracil was available, to more than 20 months today with the availability of various new chemotherapeutic and targeted agents. The use of chemotherapeutic agents — including fluoropyrimidines, irinotecan, and oxaliplatin — has been refined through decades of clinical experience. Maximal exposure, irrespective of sequence, is simply the principle of treating patients through progression with chemotherapy. Targeted therapy has emerged in the past decade, and adds complexity to the treatment principle: survival benefit has been shown with both anti–vascular endothelial growth factor and anti–epidermal growth factor receptor antibodies in individual lines of treatment, but controversy exists as to the best sequence of application. Adding to this complexity, evidence continues to evolve for the predictive value of various key biomarkers as well as the development of new agents, including aflibercept and regorafenib. In this review, the best level of evidence and a simple, yet practical, strategy will be discussed for maximising the overall survival of patients.
Persistent Identifierhttp://hdl.handle.net/10722/200532
ISSN
2015 SCImago Journal Rankings: 0.113

 

DC FieldValueLanguage
dc.contributor.authorLam, KOen_US
dc.date.accessioned2014-08-21T06:50:33Z-
dc.date.available2014-08-21T06:50:33Z-
dc.date.issued2013en_US
dc.identifier.citationHong Kong Journal of Radiology, 2013, v. 16 n. Suppl. , p. 9-16en_US
dc.identifier.issn2223-6619en_US
dc.identifier.urihttp://hdl.handle.net/10722/200532-
dc.description.abstractSimplicity is enormously complex in the treatment of metastatic colorectal cancer. In terms of survival, life expectancy of patients with metastatic colorectal cancer improved substantially from 3 to 6 months in the 1980s when only 5-fluorouracil was available, to more than 20 months today with the availability of various new chemotherapeutic and targeted agents. The use of chemotherapeutic agents — including fluoropyrimidines, irinotecan, and oxaliplatin — has been refined through decades of clinical experience. Maximal exposure, irrespective of sequence, is simply the principle of treating patients through progression with chemotherapy. Targeted therapy has emerged in the past decade, and adds complexity to the treatment principle: survival benefit has been shown with both anti–vascular endothelial growth factor and anti–epidermal growth factor receptor antibodies in individual lines of treatment, but controversy exists as to the best sequence of application. Adding to this complexity, evidence continues to evolve for the predictive value of various key biomarkers as well as the development of new agents, including aflibercept and regorafenib. In this review, the best level of evidence and a simple, yet practical, strategy will be discussed for maximising the overall survival of patients.en_US
dc.languageengen_US
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkjr.orgen_US
dc.relation.ispartofHong Kong Journal of Radiologyen_US
dc.rightsHong Kong Journal of Radiology. Copyright © Hong Kong Academy of Medicine Press.en_US
dc.subjectChemotherapy, adjuvanten_US
dc.subjectColorectal neoplasmsen_US
dc.subjectReceptor, epidermal growth factoren_US
dc.subjectVascular epidermal growth factoren_US
dc.titleFrom complexity to simplicity: best level of evidence for metastatic colorectal cancer.en_US
dc.typeArticleen_US
dc.identifier.emailLam, KO: lamkaon@hku.hken_US
dc.identifier.authorityLam, KO=rp01501en_US
dc.identifier.hkuros232238en_US
dc.identifier.volume16en_US
dc.identifier.issueSuppl.en_US
dc.identifier.spage9en_US
dc.identifier.epage16en_US
dc.publisher.placeHong Kongen_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats